Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.

@article{Appell2001ProspectiveRC,
  title={Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.},
  author={Rodney A. Appell and Peter E. Sand and Roger Dmochowski and Richard G.W Anderson and Norman R. Zinner and Daniel J Lama and Mack Roach and John Miklos and Daniel R. Saltzstein and Timothy Boone and David R. Staskin and Detlef Albrecht},
  journal={Mayo Clinic proceedings},
  year={2001},
  volume={76 4},
  pages={358-63}
}
OBJECTIVE To compare the efficacy and tolerability of extended-release oxybutynin chloride and tolterodine tartrate at 12 weeks in participants with overactive bladder. SUBJECTS AND METHODS The OBJECT (Overactive Bladder: Judging Effective Control and Treatment) study was a prospective, randomized, double-blind, parallel-group study conducted between March and October 2000 at 37 US study sites. Participants who had between 7 and 50 episodes of urge incontinence per week and 10 or more voids… CONTINUE READING